Navigation Links
Calithera Biosciences Presents Data for CB-839 in Triple-Negative Breast Cancer Models at the 2013 San Antonio Breast Cancer Symposium
Date:12/12/2013

rogen receptor positive.  In vitro treatment with CB-839 reduced cell viability and induced apoptosis in the majority of triple negative breast cancer cell lines.  CB-839 treatment also resulted in significant anti-tumor activity in two triple-negative breast cancer xenograft models: as a single agent in a patient-derived tumor with a metabolite and expression profile suggestive of high glutamine utilization, and in a second cell line model in which CB-839 demonstrated robust anti-cancer activity both as a single agent and in combination with paclitaxel.

To verify biomarker indicators for CB-839 sensitivity, Calithera researchers studied the Cancer Genome Atlas mRNA expression dataset (n=756) of primary human breast cancers and confirmed a pattern of significantly increased markers of glutaminase in triple-negative breast cancers relative to hormone-receptor driven tumors.  Similar observations were made at the metabolite level in 262 primary breast tumors, suggesting that biomarkers of glutamine utilization and high glutaminase expression may be useful in identifying patients most likely to benefit from CB-839.

Calithera presented these data today during the Tumor Cell and Molecular Biology session in a poster titled:  Antitumor Activity of the Glutaminase Inhibitor, CB-839, in Triple-Negative Breast Cancer (# P2-09-03).

About Calithera Biosciences
Calithera is discovering and developing novel small molecule oncology therapeutics that inhibit pathways critical to tumor growth and survival.  The Calithera team has the experience and the ability needed to discover novel therapeutics and advance these discoveries through clinical development.  The company is applying this expertise to build a pipeline of anti-cancer compounds that are distinct from other oncology therapeutics.  Calithera's lead clinical candidate, CB-839, blocks glutaminase, an enzyme critical to tumor metabolism, and is poised
'/>"/>

SOURCE Calithera Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Calithera Biosciences Secures $35 Million in Series D Financing
2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
4. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
5. Neurocrine Biosciences Reports First Quarter 2012 Results
6. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
7. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
8. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
9. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
10. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
11. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014 Pomerantz LLP is investigating ... ("PDL BioPharma" or the "Company") (NASDAQ: PDLI).  Such investors ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... of its officers and/or directors have violated Sections 10(b) ... On September 17, 2014, the Company ...
(Date:9/17/2014)... 17, 2014  Rebiotix Inc. announced this morning that results ... candidate, RBX2660 (microbiota suspension) will be presented in two posters ... Philadelphia from October 8-12. ... poster session on Thursday, October 9, 2014: Poster: ... 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study ...
(Date:9/17/2014)... , Sept. 17, 2014  Bayer HealthCare will present ... Foundation,s 66 th Annual Meeting, which takes place ... The data, which will be shared through poster presentations, ... patient care. Data will be presented in a scientific ... treatment modalities in hemophilia A patients, Bayer is maintaining ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PDL BioPharma, Inc. - PDLI 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4
...   , Strategic collaboration with Ipsen for marketing ... Nordics and the US , Photocure to commercialise ... Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on ... of a new commercial strategy for Hexvix, its flagship product ...
... Luminex Corporation (NASDAQ: LMNX ), today ... its annual European multiplexing technology symposium, September 28-29, 2011, ... feature scientific sessions, workshops, discussion groups, exhibitions and networking ... who are performing groundbreaking work in clinical diagnostics and ...
Cached Medicine Technology:Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 2Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 3Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 4Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 5Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 6Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 7Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 8Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna 2Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna 3Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna 4
(Date:9/17/2014)... damage to the ends of chromosomes could hold the key ... form of skin cancer according to new research from ... an important new genetic risk factor for melanoma. , It ... strongest indicators of those most at risk of developing melanoma. ... sun, as they burn more easily. , It now appears ...
(Date:9/17/2014)... North Central Surgical Center is proud to ... their top-notch services. The hospital was the recipient for ... surgery. , Hospital-wide, North Central was the recipient of ... this award for two years in a row (2013-2014). ... the nation for Patient Safety in 2014 and ranked ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Tidewater ... host recruit757’s scholarship workshop for football players and their ... Sept. 23. , Doors open at 6:30 p.m. for ... and speak to trainers and physical therapists. The workshop ... p.m. , The Newport News Tidewater Performance Center, which ...
(Date:9/17/2014)... Positive messages about the health benefits of quitting smoking ... study suggests. Although smokers who think quitting will ... harmful effects of smoking, researchers found smokers who believe ... "gain-framed," or positive, messages about how quitting will improve ... mix of both types of messages might get more ...
(Date:9/17/2014)... FRISCO, Texas (PRWEB) September 17, 2014 ... (EV-D68) outbreak that is hospitalizing scores of infants, children ... Louisiana, says Dr. Kirk Mahon, medical director of Legacy ... , “There have been no reported cases of EV-D68 ... Oklahoma and Louisiana, that could change,” he said. “Implementing ...
Breaking Medicine News(10 mins):Health News:Chromosome buffers hold key to better melanoma understanding 2Health News:North Central Surgical Center Receives Several Accolades 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 3Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:Legacy ER & Urgent Care Warns North Texans about Dangers of Enterovirus D68 2
... Medical Transcription announced today that Administrative Advantage has chosen ZyDoc,s ... , ... Hauppauge, New York (PRWEB) May ... that Administrative Advantage , a full-service medical transcription company ...
... Robert L. Williamson III, DDS of Raleigh Comprehensive and Cosmetic Dentistry ... to earn the certification for oral sedation dentistry. , ... ... Cosmetic Dentistry, Dr. Robert L. Williamson III and Associates, announced recently ...
... Access to Pixantrone through ProgramSEATTLE, May 5 Cell ... that pixantrone is now available on a named-patient basis ... healthcare professionals for the treatment of individual patients with ... standard therapies or is refractory to them. We know ...
... to Colleges and Universities , ... Baltimore, MD. (Vocus) ... has formally completed the acquisition of CMI Insurance, formerly a PSA ... Inc., the travel medical insurance entity within MEDEX Global ...
... Growth and Effective Expense ManagementContinued Progress on Debt ReductionBIRMINGHAM, ... HLS ) today reported its results of operations for ... showed consolidated net operating revenues of $475.1 million for ... for the first quarter of 2008, or an increase ...
... Every summer, valley businesses shed their business attire in exchange ... in the spirit of raising money for United Cerebral Palsy ... disabilities. This year, the theme is Camp Casual and ... 17th though businesses can choose to hold their event on ...
Cached Medicine News:Health News:Administrative Advantage Selects ZyDoc e-Transcription Platform for Clients 2Health News:Administrative Advantage Selects ZyDoc e-Transcription Platform for Clients 3Health News:Administrative Advantage Selects ZyDoc e-Transcription Platform for Clients 4Health News:Raleigh Comprehensive and Cosmetic Dentistry Earns Certification For Sedation Dentistry 2Health News:Raleigh Comprehensive and Cosmetic Dentistry Earns Certification For Sedation Dentistry 3Health News:Pixantrone Now Available in Europe on a Named-Patient Basis 2Health News:Pixantrone Now Available in Europe on a Named-Patient Basis 3Health News:Pixantrone Now Available in Europe on a Named-Patient Basis 4Health News:MEDEX Acquires CMI Insurance 2Health News:MEDEX Acquires CMI Insurance 3Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 2Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 3Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 4Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 5Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 6Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 7Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 8Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 9Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 10Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 11Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 12Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 13Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 14Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 15Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 16Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 17Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 18Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 19Health News:Valley Businesses Shedding Their Suits to Go Casual for a Cause 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: